GlassScriptPhysician profile
Efren L Rael
NPI 1356512875
$2,527.20
in general payments reported to CMS, 2019-2025
17 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $335 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $583.53 | 2024-2025 | |
| Csl Behring | $516.95 | 2024-2025 | Haegarda, Andembry, Kcentra |
| Astrazeneca Pharmaceuticals LP | $474.53 | 2024-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $326.73 | 2024-2025 | Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $138.14 | 2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $91.21 | 2025 | |
| Optinose US, INC. | $66.47 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $60.13 | 2024-2025 | Dupixent |
| Ionis Pharmaceuticals, INC. | $57.53 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $51.75 | 2025 | Ruconest |
| Biocryst US Sales Co., LLC | $35.62 | 2025 | Orladeyo |
| Galderma Laboratories, L.P. | $31.91 | 2025 | Nemluvio |
| Pfizer INC. | $25.76 | 2025 | |
| Hikma Pharmaceuticals USA | $18.26 | 2024 | Ryaltris |
| Gc Biopharma USA, INC. | $17.56 | 2025 | Alyglo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $17.08 | 2025 | Cutaquig |
| Amgen INC. | $14.04 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efren Rael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.